Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy

Biomaterials

Volumn 104, Issue , 2016, Pages 310-322

  Hassan, Hatem A F M ^a   Smyth, Lesley ^b   Wang, Julie T W ^a   Costa, Pedro M ^a   Ratnasothy, Kulachelvy ^b   Diebold, Sandra S ^b   Lombardi, Giovanna ^b   Al Jamal, Khuloud T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Cancer vaccines; Carbon nanotubes; Dendritic cells; Nanomedicine; Vaccine delivery

Indexed keywords

ANTIGENS; CARBON NANOTUBES; CELLS; CYTOLOGY; DISEASES; MEDICAL NANOTECHNOLOGY; NANOTUBES; T-CELLS; TUMORS; VACCINES; YARN;

ANTIGEN PRESENTING CELLS; B16F10 MELANOMA CELLS; CANCER IMMUNOTHERAPY; CANCER VACCINE; DENDRITIC CELLS; OLIGODEOXYNUCLEOTIDES; VACCINE DELIVERY; VACCINE DELIVERY SYSTEM;

IMMUNE SYSTEM;

CD40 LIGAND MONOCLONAL ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; MULTI WALLED NANOTUBE; OVALBUMIN; CANCER VACCINE; CARBON NANOTUBE; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MELANOMA CELL; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; THYMIDINE INCORPORATION ASSAY; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHEMISTRY; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL LINE, TUMOR; IMMUNOTHERAPY; MICE; NANOCAPSULES; NANOTUBES, CARBON; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; TREATMENT OUTCOME;

EID: 84979658428     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.07.005     Document Type: Article

References (54)

1. [1] Palucka, K., Banchereau, J., Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12 (2012), 265–277.
2. [2] Quail, D.F., Joyce, J.A., Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19 (2013), 1423–1437.
3. [3] Smyth, M.J., Ngiow, S.F., Ribas, A., Teng, M.W., Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13 (2016), 143–158.
4. [4] Kam, N.W., Liu, Z., Dai, H., Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. Angew. Chem. Int. Ed. Engl. 45 (2006), 577–581.
5. [5] Bianco, A., Kostarelos, K., Partidos, C.D., Prato, M., Biomedical applications of functionalised carbon nanotubes. Chem. Commun., 2005, 571–577.
6. [6] Kostarelos, K., Lacerda, L., Pastorin, G., Wu, W., Wieckowski, S., Luangsivilay, J., et al. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2 (2007), 108–113.
7. [7] Hassan, H.A.F.M., Smyth, L., Rubio, N., Ratnasothy, K., Wang, J.T.W., Bansal, S.S., et al. Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo. J. Control. Release 225 (2016), 205–216.
8. [8] Sun, Z., Wang, W., Meng, J., Chen, S., Xu, H., Yang, X.D., Multi-walled carbon nanotubes conjugated to tumor protein enhance the uptake of tumor antigens by human dendritic cells in vitro. Cell Res. 20 (2010), 1170–1173.
9. [9] Meng, J., Duan, J., Kong, H., Li, L., Wang, C., Xie, S., et al. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small 4 (2008), 1364–1370.
10. [10] Bianco, A., Hoebeke, J., Godefroy, S., Chaloin, O., Pantarotto, D., Briand, J.-P., et al. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J. Am. Chem. Soc. 127 (2005), 58–59.
11. [11] Zhao, D., Alizadeh, D., Zhang, L., Liu, W., Farrukh, O., Manuel, E., et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 17 (2011), 771–782.
12. [12] Fan, H., Zhang, I., Chen, X., Zhang, L., Wang, H., Da Fonseca, A., et al. Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin. cancer Res. Off. J. Am. Assoc. Cancer Res. 18 (2012), 5628–5638.
13. [13] Hennessy, E.J., Parker, A.E., O'Neill, L.A., Targeting Toll-like receptors: emerging therapeutics?. Nat. Rev. Drug Discov. 9 (2010), 293–307.
14. [14] Krieg, A.M., Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27 (2008), 161–167.
15. [15] Yarovinsky, F., Kanzler, H., Hieny, S., Coffman, R.L., Sher, A., Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity 25 (2006), 655–664.
16. [16] Wilson, N.S., Behrens, G.M., Lundie, R.J., Smith, C.M., Waithman, J., Young, L., et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7 (2006), 165–172.
17. [17] Blander, J.M., Medzhitov, R., Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440 (2006), 808–812.
18. [18] van Kooten, C., Banchereau, J., CD40-CD40 ligand. J. Leukoc. Biol. 67 (2000), 2–17.
19. [19] Quezada, S.A., Jarvinen, L.Z., Lind, E.F., Noelle, R.J., CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22 (2004), 307–328.
20. [20] Chatterjee, B., Smed-Sorensen, A., Cohn, L., Chalouni, C., Vandlen, R., Lee, B.C., et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 120 (2012), 2011–2020.
21. [21] Cohn, L., Chatterjee, B., Esselborn, F., Smed-Sorensen, A., Nakamura, N., Chalouni, C., et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J. Exp. Med. 210 (2013), 1049–1063.
22. [22] Burgdorf, S., Kautz, A., Bohnert, V., Knolle, P.A., Kurts, C., Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316 (2007), 612–616.
23. [23] Kastenmuller, W., Kastenmuller, K., Kurts, C., Seder, R.A., Dendritic cell-targeted vaccines–hope or hype?. Nat. Rev. Immunol. 14 (2014), 705–711.
24. [24] Schoenberger, S.P., Toes, R.E.M., van der Voort, E.I.H., Offringa, R., Melief, C.J.M., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998), 480–483.
25. [25] Bennett, S.R.M., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F.A.P., Heath, W.R., Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 (1998), 478–480.
26. [26] Bennett, S.R., Carbone, F.R., Karamalis, F., Miller, J.F., Heath, W.R., Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186 (1997), 65–70.
27. [27] Kreutz, M., Giquel, B., Hu, Q., Abuknesha, R., Uematsu, S., Akira, S., et al. Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. PLoS One, 7, 2012, e40208.
28. [28] Cho, H.J., Takabayashi, K., Cheng, P.M., Nguyen, M.D., Corr, M., Tuck, S., et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18 (2000), 509–514.
29. [29] Parente Pereira, A., Wilkie, S., Van der Stegen, S., Davies, M., Maher, J., Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in human T-cells. J. Biol. Methods, 1, 2014.
30. [30] Calvaresi, M., Zerbetto, F., The devil and holy water: protein and carbon nanotube hybrids. Acc. Chem. Res. 46 (2013), 2454–2463.
31. [31] Zheng, M., Jagota, A., Semke, E.D., Diner, B.A., McLean, R.S., Lustig, S.R., et al. DNA-assisted dispersion and separation of carbon nanotubes. Nat. Mater. 2 (2003), 338–342.
32. [32] Lehman, J.H., Terrones, M., Mansfield, E., Hurst, K.E., Meunier, V., Evaluating the characteristics of multiwall carbon nanotubes. Carbon 49 (2011), 2581–2602.
33. [33] Cataldo, F., A study on the thermal stability to 1000°c of various carbon allotropes and carbonaceous matter both under nitrogen and in air. Fullerenes. Nanotub. Carbon Nanostructures 10 (2002), 293–311.
34. [34] Mahajan, A., Kingon, A., Kukovecz, Á., Konya, Z., Vilarinho, P.M., Studies on the thermal decomposition of multiwall carbon nanotubes under different atmospheres. Mater. Lett. 90 (2013), 165–168.
35. [35] Schmidt, V., Giacomelli, C., Soldi, V., Thermal stability of films formed by soy protein isolate–sodium dodecyl sulfate. Polym. Degrad. Stab. 87 (2005), 25–31.
36. [36] Cartiera, M.S., Johnson, K.M., Rajendran, V., Caplan, M.J., Saltzman, W.M., The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30 (2009), 2790–2798.
37. [37] Mao, S., Germershaus, O., Fischer, D., Linn, T., Schnepf, R., Kissel, T., Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm. Res. 22 (2005), 2058–2068.
38. [38] He, C., Hu, Y., Yin, L., Tang, C., Yin, C., Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31 (2010), 3657–3666.
39. [39] Zhang, X.Q., Dahle, C.E., Baman, N.K., Rich, N., Weiner, G.J., Salem, A.K., Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J. Immunother. 30 (2007), 469–478.
40. [40] Beaudette, T.T., Bachelder, E.M., Cohen, J.A., Obermeyer, A.C., Broaders, K.E., Frechet, J.M., et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol. Pharm. 6 (2009), 1160–1169.
41. [41] Heit, A., Schmitz, F., Haas, T., Busch, D.H., Wagner, H., Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur. J. Immunol. 37 (2007), 2063–2074.
42. [42] Tao, Y., Zhang, Y., Ju, E., Ren, H., Ren, J., Gold nanocluster-based vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. Nanoscale 7 (2015), 12419–12426.
43. [43] de Faria, P.C.B., dos Santos, L.I., Coelho, J.P., Ribeiro, H.B., Pimenta, M.A., Ladeira, L.O., et al. Oxidized multiwalled carbon nanotubes as antigen delivery system to promote superior CD8(+) T cell response and protection against Cancer. Nano Lett. 14 (2014), 5458–5470.
44. [44] Schlosser, E., Mueller, M., Fischer, S., Basta, S., Busch, D.H., Gander, B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26 (2008), 1626–1637.
45. [45] Li, W.M., Dragowska, W.H., Bally, M.B., Schutze-Redelmeier, M.-P., Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21 (2003), 3319–3329.
46. [46] Hatzifoti, C., Bacon, A., Marriott, H., Laing, P., Heath, A.W., Liposomal co-entrapment of CD40mAb induces enhanced IgG responses against bacterial polysaccharide and protein. PLoS One, 3, 2008, e2368.
47. [47] Rosalia, R.A., Cruz, L.J., van Duikeren, S., Tromp, A.T., Silva, A.L., Jiskoot, W., et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials 40 (2015), 88–97.
48. [48] Khanna, R., Cooper, L., Kienzle, N., Moss, D.J., Burrows, S.R., Khanna, K.K., Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J. Immunol. 159 (1997), 5782–5785.
49. [49] Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., Alber, G., Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184 (1996), 747–752.
50. [50] Haswell, L.E., Glennie, M.J., Al-Shamkhani, A., Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur. J. Immunol. 31 (2001), 3094–3100.
51. [51] Broos, S., Sandin, L.C., Apel, J., Totterman, T.H., Akagi, T., Akashi, M., et al. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(gamma-glutamic acid) nanoparticles. Biomaterials 33 (2012), 6230–6239.
52. [52] Gu, L., Ruff, L.E., Qin, Z., Corr, M., Hedrick, S.M., Sailor, M.J., Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody. Adv. Mater. 24 (2012), 3981–3987.
53. [53] Bachmann, M.F., Jennings, G.T., Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10 (2010), 787–796.
54. [54] Fadel, T.R., Sharp, F.A., Vudattu, N., Ragheb, R., Garyu, J., Kim, D., et al. A carbon nanotube-polymer composite for T-cell therapy. Nat. Nanotechnol. 9 (2014), 639–647.